Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 1Leiomyoma 1

Interventions

Rituximab 67Cyclophosphamide 39Vincristine 33Prednisone 31Doxorubicin 25Lenalidomide 18Radiotherapy 16Bendamustine Hydrochloride 14Peripheral Blood Stem Cell Transplantation 10Filgrastim 10Etoposide 10Prednisolone 8tofacitinib 7obinutuzumab 6ibritumomab tiuxetan 6fludarabine 6VAP-cyclo protocol 6Mitoxantrone 6Methylprednisolone 6Deoxycholic Acid 6Cytarabine 6Melphalan 5Dexamethasone 5Carmustine 5ibrutinib 4fludarabine phosphate 4R-CHOP protocol 4Methotrexate 4Interferon-alpha 4Idarubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, Follicular × Iron × Clear all
NCT03993288 2021-07-12

Study to Test the Hypothesis of Non-inferior Efficacy and Safety of Ferrum LekĀ® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable Tablets (Lek d.d., Slovenia), as Compared With MALTOFERĀ® (Vifor S.A., Switzerland), in Subjects With Mild and Moderate Iron Deficiency Anemia.

Sandoz

Phase 3 Completed
267 enrolled 14 charts
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚔